Page 2 - Aurobindo Pharma

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Fire at Aurobindo Pharma's Andhra unit halts production temporarily

Aurobindo Pharma on Friday said a fire accident at Unit-IV of its wholly-owned arm APL Healthcare Ltd at Naidupeta in Andhra Pradesh has resulted in production disruption temporarily. In a regulatory filing, the company said on September 18, 2025, at around 8:50 am, a small fire incident occurred in granulation area-10 of Unit IV of APL Healthcare, situated at Naidupeta, Andhra Pradesh (SEZ Unit), due to a short circuit. The fire spread to a panel, affecting granulation area-10 and causing partial damage to granulation area-8. Out of the total 19 lines in the said Unit, 2 lines have been impacted for about two weeks, it added. The fire incident was immediately controlled through the in-house fire hydrant team, along with support from external fire tenders, and there were no casualties or injuries, the company said. "The incident resulted in a temporary production impact estimated at about 3 per cent of the monthly capacity of the said unit. Necessary steps have been initiated for .

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

Stocks to Watch, Aug 21: India Cements, Clean Science, Railtel, Aurobindo

Stocks to Watch today, August 21, 2025: From India Cements to Clean Science and Technology, here are a few stocks that investors and traders will eye; check the full list

Aurobindo Pharma leads $5 billion race to acquire Prague-based Zentiva

Shortly after reports of the potential acquisition surfaced, Aurobindo clarified that no binding agreement or definitive decision has been made regarding the deal

Stocks to Watch, Aug 18: Vi, Glenmark Pharma, BPCL, NTPC, M&M, PVR Inox

Stocks to Watch today, August 18, 2025: From Vodafone Idea to BPCL, here is a list of stocks that will be on investors' and traders' radar

Aurobindo Pharma expects China plant to break even at Ebitda level in FY26

Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA (earnings before interest, taxes, depreciation, and amortisation) level by Q3 FY26," Subramanian said in an analyst call. He noted that around USD 145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about USD 70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to

Stocks to Watch today, Aug 5: IndusInd Bank, DLF, Aurobindo Pharma, Bosch

Stocks to Watch today, August 5, 2025: DLF, Aurobindo Pharma, IndusInd Bank, Bosch, and Inox India are some of the key stocks to watch today

Aurobindo Pharma stock falls 2% after Q1 results; check key numbers here

Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter last year

Aurobindo Pharma Q1 PAT falls 10% on drop in API sales, US market revenue

Aurobindo Pharma reports a 10.2% YoY drop in Q1 FY26 PAT due to lower API sales and US market revenue, while its European and growth markets continue to show positive momentum

Aurobindo Pharma Q1 results: Profit drops 10% to ₹824 crore on US sales

Aurobindo Pharma on Monday reported a 10 per cent decline in its consolidated net profit to Rs 824 crore for the June quarter, hit by dip in sales in the US and API business vertical. The Hyderabad-based drug maker posted a net profit of Rs 918 crore for the April-June quarter of last fiscal. Revenue from operations increased to Rs 7,868 crore for the June quarter as against Rs 7,567 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing. "We started the year steadily, with our European business maintaining strong growth momentum and our core US business showing resilience despite temporary challenges from destocking and seasonal dynamics," K Nithyananda Reddy, Vice-Chairman and Managing Director of the company said. The company's disciplined execution, operational initiatives, and recent US acquisition strengthens commercial footprint and accelerates growth potential, he added. The board of directors at its meeting held on Monday has approved the payment of ..

Q1 results today: Shree Cement, Aurobindo Pharma, DLF, 103 others on Aug 4

Q1 FY26 company results, Aug 4: Marico, Aditya Birla Capital, Ather Energy, Bosch, Delta Corp, Siemens Energy India, Godfrey Phillips, and Inox India will release their April-June quarter report

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. The Hyderabad-based drugmaker has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare, the company said in a statement. The agreement allows Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets, it added. This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months. "We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to t

Aurobindo Pharma recalls over 4,600 bottles of painkiller in US market

The drug, Acetaminophen Tablets (325 mg), is being recalled due to manufacturing deviations from Current Good Manufacturing Practices, following complaints of brown tablet discolouration

These 5 pharma stocks can fall up to 12% as technical charts flag caution

Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.

Stocks to Watch, May 27: Aurobindo Pharma, Nazara Tech, IndiGo, Lupin, TCS

Stocks to Watch on Tuesday: Aurobindo Pharma, Nazara Tech, IndiGo, Lupin, TCS, PG Electroplast and Sagility India are among the stocks to watch today, May 27, 2025

Aurobindo Pharma Q4 results: Profit dips to ₹903 cr, revenue up 11%

Aurobindo Pharma on Monday reported a marginal dip in its consolidated profit after tax to Rs 903 crore for the fourth quarter ended March 2025. The Hyderabad-based drug maker posted a profit after tax (PAT) of Rs 907 crore in the January-March quarter of FY24. Its total revenue from operations stood at Rs 8,382 crore for the fourth quarter compared to Rs 7,580 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing. For the full year ended March 31, 2025, the company said its PAT rose 10 per cent to Rs 3,484 crore against Rs 3,169 crore in FY24. The total revenue from operations rose to Rs 31,724 crore last fiscal from Rs 29,002 crore in 2023-24. "We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. The drug firm's European operation

Aurobindo Pharma Q4 net dips 0.5%, revenue up 10.5% to Rs 8,382 cr

US and Europe markets drive growth as company posts flat profit for Q4 FY25; files 9 ANDAs and launches 5 new products during the quarter